Chemical formula: C₅₉H₈₄N₁₆O₁₂ Molecular mass: 1,209.398 g/mol
Leuprorelin is indicated for:
Population group: men, only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Treatment of central precocious puberty (girls under 9 years of age, boys under 10 years of age).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adolescents (12 years - 18 years old) , adults (18 years old or older)
Management of endometriosis, including pain relief and reduction of endometriotic lesions.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
As treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.
As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Leuprorelin is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
